Search Thermo Fisher Scientific
OncomineWorld 2025 is now on demand
Now in its sixth year, OncomineWorld meetings have united thousands of scientists and professionals from around the globe to advance genomic profiling in clinical oncology research.
Watch our on-demand presentations spanning a variety of clinical oncology research topics. The presentations explore liquid biopsy applications, comprehensive genomic profiling, and NGS profiling for myeloid malignancies, among many other topics.
Oncomine World is back with new features!
In its sixth year, OncomineWorld unites thousands of global scientists and professionals to advance genomic profiling in clinical oncology research.
Agenda Highlights:
- Next-Generation Sequencing Education: Presentations from Oncomine Solutions users.
- Oncomine Clinical Research Grant: Learn about the grant and hear from our pharma partners.
Why Attend OncomineWorld 2025?
Earn CE Credits*:
- Deepen your understanding of NGS in precision oncology and routine practice.
- Learn from peers' experiences.
- Focus on liquid biopsy, comprehensive genomic profiling in solid tumors, and biomarker testing in myeloid and lymphoid malignancies.
Oncomine Clinical Research Grant (OCRG):
- Learn how Thermo Fisher Scientific supports oncology research from Dr. Jose Luis Costa and OCRG awardees.
- Discover the upcoming call for applications (April 1st – 30th).
Insights from Pharma Partners:
- Understand strategies in precision oncology.
Engage and Learn:
- Explore virtual labs with educational resources.
- Participate in Ion Torrent Genexus NGS System demonstrations.
Agenda
Moderator
Dr. Luca Quagliata, PhD, BCMAS, COA; Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific
General education presentations
Experience with Rapid NGS in solid tumor genomic profiling
Dr. Omshree Shetty, PhD; Assistant Professor and Scientific Officer, National Coordinator for Molecular Pathology Quality Assurance Program, Tata Memorial Hospital, Mumbai, India
Introduction to liquid biopsies for precision oncology: A focus on treatment selection and monitoring in late stages
Dr. Simon Heeke, PhD; Head of Liquid Biopsy Translational Group, Assistant Professor, Thoracic Head and Neck Oncology, MD Anderson Cancer Center, Houston, Texas, USA
Implementation of an ISO 15189-accredited next-generation sequencing service for cell-free total nucleic acid (cfTNA) analysis: The experience of a clinical diagnostic laboratory
Ms. Amy Connolly, MSc; Specialist Medical Scientist, Histopathology Department Cork University Hospital, Cork, Ireland
B-cell receptor clonality assessment using next generation sequencing in gastric mucosa-associated lymphoid tissue lymphoma
Dr. Rer. Nat. Chidimma Akpa; Senior Associate, Department of Hematology, Oncology, and Cancer Immunology, Charité Universitätsmedizin Berlin, Germany
Reimbursement for liquid biopsy in the United States: Understanding recent changes and the implications
Mr. Charles Mathews, MPP; Partner, ClearView HealthCare Partners
Clinical research presentations
Measurable Residual Disease research in AML using Oncomine NGS analysis
Dr. Jong-Mi Lee, MD, PhD; Assistant Professor, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Oncomine Clinical Research Grants: Supporting clinical oncology research
Dr. Jose Luis Costa, PhD, BCMAS; Global Director, Scientific Affairs, Thermo Fisher Scientific
HRD assessment using Oncomine™ Comprehensive Assay Plus
Dr. Elaine Wong Ho, PhD; Senior Product Manager, Oncology, Thermo Fisher Scientific
Evaluation of Oncomine Comprehensive Assay Plus NGS Panel and OncoScan CNV Assay for homologous recombination deficiency detection
Dr. Lone Schejbel, PhD; Molecular Biologist, Department of Pathology, Herlev and Gentofte Hospital, Denmark
Rapid genomic profiling of lymphoid malignancies
Mr. Robert Baker, BSc, MIBMS; Molecular Haematology Operational Manager, Health Services Laboratories LLP, United Kingdom
Analysis of central nervous system tumor ctDNA from cerebrospinal fluid
Dr. Leomar Ballester, MD, PhD; Assistant Professor, Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center
Clinical diagnostics presentations
Precision medicine EMEA strategy and operations
Dr. Leonie de Visser, PhD; Portfolio and Alliance Lead – Precision Medicine EMEA Strategy & Operations Johnson & Johnson Innovative Medicine
Innovative medicine experience and impact of clinical oncology diagnostics using Oncomine Dx Express Test
Dr hab. n. med. Bartłomiej Budny; Head of Department of Cancer Molecular Diagnostics, Wielkopolska Center of Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland, Poland
*To redeem your Continuing Education credits, locate the presentation you watched on this webpage and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, click here. CE credits are recognized by several accreditation bodies but may not be applicable in all countries.